Maxalt Migräne (Rizatriptan Benzoate)

Rizatriptan selectively activates 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve fibers. This activation causes vasoconstriction of dilated intracranial arteries and blocks the release of inflammatory neuropeptides, interrupting the migraine cascade and providing rapid symptom relief.

The specific dose of Maxalt Migräne is determined by the prescribing healthcare professional based on the individual’s medical condition, response to therapy, and any concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for rizatriptan in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Rizatriptan belongs to the triptan class, which is generally more effective for moderate to severe migraine attacks than simple analgesics such as NSAIDs. Compared with other triptans, rizatriptan has a relatively rapid onset of action and a favorable tolerability profile, though individual response can vary.

Store Maxalt Migräne at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Maxalt Migräne is taken orally as a tablet. The tablet should be swallowed whole with a glass of water at the first sign of a migraine attack. If needed, a second dose may be taken after at least two hours, but only under the guidance of a healthcare professional.

The most serious risks include coronary vasospasm or myocardial ischemia, especially in patients with underlying cardiovascular disease, and serotonin syndrome when combined with other serotonergic drugs. Patients should seek immediate medical attention if they experience chest pain, severe hypertension, or signs of an allergic reaction.

Maxalt Migräne should be avoided in individuals with known hypersensitivity to rizatriptan or any component of the tablet, those with uncontrolled hypertension, significant cardiovascular disease (e.g., recent myocardial infarction, severe angina), or who are currently taking MAO inhibitors, other triptans, or ergot derivatives.